IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China-Study Design and Baseline Characteristics
Ji, Linong1,2; Zhang, Puhong2; Weng, Jianping3; Lu, Juming4; Guo, Xiaohui1; Jia, Weiping5; Yang, Wenying6; Zou, Dajin7; Zhou, Zhiguang8; Pan, Changyu9; Gao, Yan1; Li, Xian2; Zhu, Dongshan2; Li, Ying2; Wu, Yangfeng2; Garg, Satish K.10
刊名DIABETES TECHNOLOGY & THERAPEUTICS
2015-10-01
DOI10.1089/dia.2015.0054
17期:10页:735-744
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]GLYCEMIC CONTROL ; PRIMARY-CARE ; CLINICAL-PRACTICE ; GLUCOSE CONTROL ; PREVALENCE ; THERAPY ; DETEMIR ; ASSOCIATION ; MANAGEMENT ; RESISTANCE
英文摘要

Background: Efficacy of basal insulin (BI) has been well studied by randomized controlled trials, but the impact of BI on glycemic control in the real world has not been well documented. The Observational Registry for BI Treatment (ORBIT) study is designed to evaluate the real-life outcomes of BI in China.

Materials and Methods: Participants with type 2 diabetes (n=19,894), from December 2011 to June 2013, inadequately controlled on oral hypoglycemic agents (OHAs) were initiated on BI treatment from 209 hospitals in all the eight regions in Mainland China. Data for each patient on use of OHAs and insulin (type and dose), glycemic control, hypoglycemic episodes, body weight, quality of life, and costs were collected at baseline and 3 and 6 months.

Results: For the 18,995 participants who were eligible for baseline analysis, mean +/- SD age was 55.4 +/- 10.4 years, with 52.5% males. The mean duration of diabetes was 6.4 +/- 5.3 years and was positively associated with the economic level of eight regions. Before initiation of BI, patients had a mean hemoglobin A1c level of 9.6 +/- 2.0% with a fasting plasma glucose level of 11.7 +/- 4.0 mmol/L. Of the patients, 35.5% had some diabetes complications. Metformin, sulfonylureas, and alpha-glycosidase inhibitors were the most commonly used OHAs. The proportions of patients using one, two, or more than two OHAs before BI initiation were 48.4%, 42.7%, and 8.9%, respectively.

Conclusions: To the best of our knowledge, the ORBIT study is the largest registry study to evaluate glycemic outcomes and safety of BI in real-world China. Baseline data indicate delays in initiation of BI in the majority of patients with type 2 diabetes in China.

语种英语
WOS记录号WOS:000360967700011
资助机构Sanofi-Aventis (Shanghai, China)
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64557
专题北京大学第二临床医学院
北京大学第一临床医学院_内分泌内科
作者单位1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Beijing 100088, Peoples R China
3.Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China
4.Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
5.Shanghai 6th Hosp, Shanghai, Peoples R China
6.China Japan Friendship Hosp, Beijing, Peoples R China
7.Second Mil Med Univ, Shanghai, Peoples R China
8.Xiangya Second Hosp, Changsha, Hunan, Peoples R China
9.Beijing 301 Mil Gen Hosp, Beijing, Peoples R China
10.Univ Colorado Denver, Barbara Davis Ctr Diabet, Aurora, CO USA
推荐引用方式
GB/T 7714
Ji, Linong,Zhang, Puhong,Weng, Jianping,et al. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China-Study Design and Baseline Characteristics[J]. DIABETES TECHNOLOGY & THERAPEUTICS,2015,17(10):735-744.
APA Ji, Linong.,Zhang, Puhong.,Weng, Jianping.,Lu, Juming.,Guo, Xiaohui.,...&Garg, Satish K..(2015).Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China-Study Design and Baseline Characteristics.DIABETES TECHNOLOGY & THERAPEUTICS,17(10),735-744.
MLA Ji, Linong,et al."Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China-Study Design and Baseline Characteristics".DIABETES TECHNOLOGY & THERAPEUTICS 17.10(2015):735-744.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ji, Linong]的文章
[Zhang, Puhong]的文章
[Weng, Jianping]的文章
百度学术
百度学术中相似的文章
[Ji, Linong]的文章
[Zhang, Puhong]的文章
[Weng, Jianping]的文章
必应学术
必应学术中相似的文章
[Ji, Linong]的文章
[Zhang, Puhong]的文章
[Weng, Jianping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。